The eructation row and the documents around it
Table 1 in section 6.1 pools two placebo-controlled weight trials of up to 72 weeks, ATTAIN-1 in adults without diabetes and ATTAIN-2 in adults with type 2 diabetes, and lists reactions seen in at least 5% of treated people and more often than on placebo [1]. Eructation is one of its 13 rows. The Medication Guide puts belching on its list of the most common side effects [2].
No other regulator has published figures. The European Medicines Agency’s committee recommended approval on 15 October 2026, but there is no EMA product information yet [3], and Health Canada’s database has no Foundayo™ or orforglipron entry [4].
| Group | Adults | Eructation |
|---|---|---|
| Placebo | 1,576 | 1% |
| Foundayo™ 5.5 mg | 1,051 | 6% |
| Foundayo™ 9 mg | 1,055 | 8% |
| Foundayo™ 17.2 mg | 1,049 | 8% |
How large the jump really is
Placebo burping was the lowest background rate in the whole table, so even a modest number on the tablet is a big multiple of it. Using the label’s whole-number percentages, burping on Foundayo™ was six times placebo on 5.5 mg and eight times on 9 mg and 17.2 mg. For comparison, nausea reached about three and a half times placebo and vomiting six times, both on the top dose [1].
Rounded percentages can exaggerate or shrink a ratio, so it helps to go back to counts. The two trial registries together list 14 of 1,576 people on placebo with burping, about 0.9%, and 65 of 1,051 (6.2%), 81 of 1,055 (7.7%) and 83 of 1,049 (7.9%) on the three doses, which matches the label’s rounded figures [5][6]. In absolute terms, burping added about five to seven people per hundred; nausea added far more. So burping affected fewer people than the headline stomach reactions but was the most specific to the tablet.
The rate rose between 5.5 mg and 9 mg and then stayed flat [1]. The label’s dose schedule moves up in steps at least 30 days apart to limit stomach and bowel reactions, so the weeks after the step to 9 mg are a sensible place to look in your own notes [1].
Trial by trial
The trials used an investigational formulation. In ATTAIN, the 6, 12 and 36 mg trial doses correspond to Foundayo™ 5.5, 9 and 17.2 mg [1]; the ACHIEVE diabetes trials also tested a 3 mg dose that has no stated tablet equivalent.
| Trial [source] | Comparison group | Orforglipron groups |
|---|---|---|
| ATTAIN-1, obesity without diabetes, 72 weeks [5] | Placebo 10 of 948 (1.1%) | 6 mg 44 of 723 (6.1%); 12 mg 43 of 724 (5.9%); 36 mg 55 of 728 (7.6%) |
| ATTAIN-2, obesity with type 2 diabetes, 72 weeks [6] | Placebo 4 of 628 (0.6%) | 6 mg 21 of 328 (6.4%); 12 mg 38 of 331 (11.5%); 36 mg 28 of 321 (8.7%) |
| ACHIEVE-1, early type 2 diabetes, 40 weeks, every event listed [8] | Placebo 0 of 138 | 3 mg 5 of 143 (3.5%); 12 mg 6 of 137 (4.4%); 36 mg 10 of 141 (7.1%) |
| ACHIEVE-3, type 2 diabetes, open label, 52 weeks [7] | Oral semaglutide 7 mg 17 of 426 (4.0%); 14 mg 14 of 425 (3.3%) | 12 mg 42 of 424 (9.9%); 36 mg 32 of 423 (7.6%) |
What the comparison shows
- Every trial points the same way: burping was uncommon on placebo and several times more frequent on orforglipron [5][6][8].
- The highest figure, 11.5% in ATTAIN-2, came on the middle dose rather than the top one [6]. The registries do not explain this, and groups of about 330 people leave room for chance.
- Oral semaglutide also caused burping in ACHIEVE-3, but about half as often [7]. The trial publication reports more stomach and bowel events overall on orforglipron, 59% and 58%, than on semaglutide, 37% and 45% [9].
- ACHIEVE-3 was open label, so participants knew which tablet they took, which can influence reporting [9]. It also studied type 2 diabetes, which the US label does not cover; the EU opinion does include it [1][3].
Why a slower stomach may bring up more air
- From the label: Foundayo™ delays stomach emptying, most after the first dose and less as treatment goes on [1]. The label does not link eructation to this by name.
- Plausible but not measured: MedlinePlus explains that a belch happens when air stretches the upper stomach and the muscle at the lower end of the oesophagus relaxes to let it out [10], and Cleveland Clinic lists gastroparesis, a slow-moving stomach, among conditions that cause belching [11]. No orforglipron study has tested whether slower emptying is what drives the extra burping.
- General knowledge: belching is a normal way of releasing swallowed air, and MedlinePlus notes it can relieve nausea, indigestion or heartburn [10].
Other reasons for frequent burping
Burping often comes with its table neighbours, indigestion (12% to 16%) and reflux disease (6% to 7%), both linked to belching in general sources and covered on our Foundayo™ heartburn page [1][11].
Cleveland Clinic names swallowed air as the most common cause of excessive belching: eating or drinking quickly, talking while eating, chewing gum, sucking hard sweets, fizzy drinks, smoking, loose dentures, postnasal drip, mouth breathing, snoring and CPAP use [11]. Snoring and CPAP are worth a thought here, because 11% of people in the Foundayo™ trials had obstructive sleep apnoea [1]. Beans, lentils, cabbage, onions, broccoli and cauliflower can add to it, as can gastritis, peptic ulcers, lactose intolerance, H. pylori infection, small intestinal bacterial overgrowth and anxious air swallowing [11].
What general sources say helps
MedlinePlus suggests lying on your side or in a knee-to-chest position until the gas passes, and avoiding chewing gum, eating quickly and gas-producing foods and drinks [10]. Cleveland Clinic adds sitting down to eat and taking your time, cutting back on fizzy drinks and alcohol, and regular exercise that strengthens the core [11]. If belching is excessive and does not go away, it says a provider may look for an underlying condition and may suggest avoiding certain foods, a low-FODMAP plan or a dietitian [11].
Neither source names a medicine for burping. If you are thinking of taking something from the pharmacy, ask the pharmacist first: the Foundayo™ label says the tablet slows stomach emptying and can change how other oral medicines are absorbed [1].
What the label leaves out
- Smell or taste: neither the label nor the Medication Guide describes the character of the burps [1][2]. The label does report a separate taste change, dysgeusia, in 0.9% on Foundayo™ against 0.3% on placebo [1].
- Timing: its sentence about reactions easing over time names nausea, vomiting and diarrhoea, not burping [1].
- Stopping: there is no figure for burping alone. All stomach and bowel reactions together led 3% to 6% of people on Foundayo™ to stop, against 0.7% on placebo [1].
Foundayo™ is a trademark of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Eli Lilly and Company.
When to get help
The signs and contact information below come from this article’s sourced guidance.
Emergency
- Burping with chest pain or pressure, especially severe, crushing or spreading to the arm or jaw
Contact: Emergency care (911 or your local emergency number)
Cleveland Clinic [11]
- Severe stomach pain that will not go away, with or without vomiting, sometimes felt in the back
Contact: Stop Foundayo™ and call your provider right away
Foundayo™ Medication Guide [2]